CAJ | 학술논문

二肽基肽酶-4(DPP-4)抑制药是一类新型口服降糖药，可改善血糖控制，并且不会增加体质量和诱发低血糖，在2型糖尿病的治疗中发挥着越来越重要的作用。本文对DPP-4抑制药作用机制、药动学及临床应用等方面的研究进展进行综述，以期为临床应用提供一定参考。
이태기태매-4(DPP-4)억제약시일류신형구복강당약，가개선혈당공제，병차불회증가체질량화유발저혈당，재2형당뇨병적치료중발휘착월래월중요적작용。본문대DPP-4억제약작용궤제、약동학급림상응용등방면적연구진전진행종술，이기위림상응용제공일정삼고。
Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new kind of oral hypoglycemic drugs, can significantly lower blood glu-cose levels in the patients with type 2 diabetes without common side effects such as body weight gain, hypoglycemia and gastrointestinal disturbances. Therefore, DPP-4 inhibitors play an increasingly important role in the treatment of type 2 diabetes. In this review, the re-search progress in the action mechanism, pharmacokinetics and clinical applications of DPP-4 inhibitors was summarized in order to provide reference for the clinical application.